That’s not right. That may have been true when that paper was published but isn’t true now. The effectiveness of the gem + abr combo in LAPC is most certainly known. LAPACT trial, published in lancet gastro - hepatology, Philip, Vol 5, issue 3 p285-294, March 1, 2020. 107 patients with LAPC given this chemo, looks to be at similar doses/amounts as used in Oncosil PanCO trial. Results: objective response rate (the % getting at least 30% reduction in tumour diameter) = 33.6%. median progression free survival =10.9 m median overall survival =18.8m
there’s a slide available online (google images) I couldn’t paste here but shows the plot of best tumour diameter reduction in all patients in LAPACT, looks very consistent with the plots in the MPACT paper cited by miksha77. A number get major shrinkage of >40% There’s absolutely no doubt the current standard of care chemo used in all these trials has an appreciable effect on pancreatic tumour size, the real question is does adding the device have any additional shrinkage effect. At best going by this info it could be marginal but we’ll only know through a proper randomised controlled trial which is OSL’s plan anyway I believe.
OSL Price at posting:
11.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)